Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung.
Site Search
To date, the CF Foundation has funded more than $1 million to programs created by and for the CF community.
ViaNautis’ non-viral delivery mechanism, polyNaut®, aims to improve delivery of genetic therapies to the cells of people with CF.
Funding will support clinical trials for therapy that could help improve digestion in people with CF
Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
The Board’s review put Coloradans with CF at the center of the discussion, helping to preserve vital access to Trikafta®.
Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
The Cystic Fibrosis Foundation mourns the passing of long-standing CF community champion and philanthropic leader who helped to raise more than $500 million toward the CF cause.
The Foundation is committed to improving health outcomes for people with cystic fibrosis from underrepresented groups by supporting research projects advancing our understanding of barriers to health equity.